MATN

Matinas BioPharma Holdings filed a notice of delisting or failure to satisfy a continued listing rule (Item 3.01). This indicates potential issues with exchange listing requirements, often leading to significant volatility and negative investor sentiment.

AI-generated: summaries written by AI from the linked sources. How we use AI